1.      R.Detels , A. Munoz, G. McFarlane et al., “Effectiveness of potent antiretro viral therapy on time to AIDS and death in men with known HIV infection duration , “ Journal of the Americal Medical Assocation , vol .280, No.17,pp 1497-1503, 1998. View at Publisher. View at Google Scholar View at scopus.

2.      F.J.Palella Jr., K.M.Delaney, A.C. Moorman et al., “ Declining morbidity and Mortality among patients with advanced human immunodeficiency virus infection, “ The New England Jounral of Medicine , vol.338 No.13 pp.853-860, 1998. View at Publisher view at Google Scholar View at PubMed . view at Scopus.

3.      T.Powels, D. Robinson, J.Stebbing et al., “ Highly Active antiretro viral therapy and the incidence of non – AIDS – defining cancers in people with HIV infection , “ Journal of Clinical Oncology, Vol.27 no.6 pp 884-890 2009. View at Publisher. View at Google Scholar . View at Pubmed, View at Scopus.

4.      R.J. Bedimo, K.A. McGinnis, M.Dunlap, M.C. Rodriguez- Barradas, and A.C. Justice, “ Incidence of non-AIDS defining malignancies in HIV infected versus non infected patients in the HAART Era: Impact of immunosuppression, “ Journal of Acquired Immune Deficiency Syndromes, Vol.23, no.13,pp.  203-208,2009. View at Publisher View at Google Scholar. View at PubMed . View at Scopus.

5.      B.Marin, R.Thiebaut, H.C.Bucher et al., “ Non- AIDS – defining deaths and immunodeficiency in the era of combination antiretro viral therapy, “ AIDS, vol.23, no.13,pp. 1743-1753.

6.      S. Franceschi, M. Lise, G.M.Clifford et al., “ Changing patterns of cancer incidence in the early and late HAART periods : the swiss HIV cohort study,” British Journal of Cancer, Vol.103, no.3,pp.416-422,2010. View at Publisher ., View at Google Scholar. View at Pubmed . View at Scopus.

7.      L.A.Ries, C.L. Kosary, B.F. Hankey, et al., Eds.,SEER Cancer Statistics Review : 1973- 1994, NIH Publ no. 97-2789, National Cancer institute, Bethesda, Md, USA,1997.

8.      E.Chimienti, M. Spina, R. Gastaldi, et al., “ Clinical Characteristics and Outcome of 290 patients with Hodgkin’s disease and HIV infection (HD- HIV) in pre and HAART (highly active anti-retro viral therapy) era, “ Annals of Oncology, Vol.19,2008 Abstract No.168. View at Google Scholar.

9.      D.Serraino, A.Carbone, S. Franceschi, and U. Tirelli, “ Increased frequency of Lymphocyte depletion and mixed cellularity subtypes of Hodgkin’s disease in HIV- infected patients, “ European Journal of Cancer A, Vol.29, NO.14,pp. 1948-1950,1993 . View at Publisher. View at Google Scholar. View at Scopus.

10.  A.M. Levine, “ Hodgkin Lymphoma: to the HAART of the matter, “ Blood, Vol.108, no. 12, pp.3630-3631, 2006 view at Publisher. View at Google Scholar. View at Scopus.

11.  R.J.Biggar, E.S. Jaffe, J.J.Goedert, A. Chaturvedi , R. Pfeiffer, amd E. A. Engles. “ Hodgkin Lymphoma and immune deficiency in persons with HIV/AIDS, “Blood, Vol.108, No.12 pp.3786-3791,2006 View at publisher .View at Google Scholar. View at PubMed. View at scopus.

12.  K.l. Grogg., R.F. Miler, and A.Dogan. “ HIV infection and lymphoma, “ Journal of Clinical Pathology, Vol.60 no.12, pp.1365-1372, 2007. View at Publisher . View at Pubmed. View at Scopus.

13.  U. Tirelli, D. Errante, R. Dolcetti et al., “ Hodking’s disease and human immunodeficiency virus infection: Clinicopathologic and virologic features of 114 patients form the Italian Cooperative Group on AIDS and Tumours.” Journal of Clinical oncology, Vol.13, no.7,pp.1758-1767,1995. View at Google Scholar . View at Scopus.

14.  Carbone, A.Gloghini, L.M.Larocca et al., “ Human immunodeficiencny virus-associated Hodgkin’s disease derives from Post-germinal center B Cells, “ Blood, Vol.93 no.7 pp.2319-2326 View at Google Scholar. View at Scopus

15.  S.A.Rezk and L.M. Weiss, “ Epstein-Barr Virus-associated lymphoproliferative disorders, “ human Pathology, vol.38, no.9., pp.1293-1304. 2007. View at Publisher view at Google Scholar View at Pubmed . View at Scopus.

16.  J.W. Said, “ Immunodeficiency – related hodgkins lymphoma and its mimics, “ Advances in Anatomic Pathology, Vol.14 no.3 pp.189-194, 2007. View at Publisher. View at Google Scholar. View at PubMed . View at Scopus.

17.  Carbone, A.Gloghini, L.M.Larocca et al., “ EBV- Associated lympho proliferative disorders: Classification and treatment, “Oncologist, Vol.13, no.5, pp.577-585, 2008. View at Publisher . View at Google Scholar. View at Pubmed . View at Scopus.

18.  M. Guiguet, F. Boue, J.Cadranel , J.M. Lang, E.Rosenthal, and D.Costagliola, “ Effect of Immunodeficiency, HIV viral load, and antiretro viral therapy on the risk of individual malignances (FHDH-ANRS CO4) : a Propspective Cohors study,” The Lancet Oncology, vol.10 , no.12,pp.1152-1159,2009.

19.  J.M. Andrieu, S. Roithmann, J.M.Tourani et al., “Hodgkin’s disease during H1V1 infection: The French registry experience, “ Annals of oncology, Vol.4, no 8 pp.635-641, 1993.

20.  R.Rubio, “Hodgkin’s disease associated with human immunodeficiency virus infection : a clinical study of 46 cases, :Cancer , vol.73, no.9 pp.2400-2407, 1994.

21.  D.Hasenclever and V. Diehl, “A prong-ostic score for advanced Hodgkin’s dise-ase, “The New England Journal of Medi-cine, Vol.339, no.21 pp.1506-1514,1998.

22.  J.Berenguer, P. Miralles, J.M.Rivera et al., “ Characteristics and outcome of AIDS-related Hodgkin lymphoma before and after the introduction of highly active antiretro viral therapy, “ Journal of Acquired Immune Deficiency Syndromes, Vol. No. 4 , pp.422-428, 2008.